Tertius News is an AI-native newsroom: an AI model reads the linked source articles below and extracts what each outlet reported, so you can compare their coverage side by side. How this works →
New information became available — this story may be updated shortly.
Merck, Moderna claim encouraging melanoma vaccine trial results
Moderna and Merck announced that their personalized mRNA-based cancer vaccine intismeran, combined with Keytruda, significantly reduced melanoma recurrence in a Phase 3 trial. The results, hailed as a 'landmark moment' by researchers, sent Moderna's stock soaring and marked the first successful late-stage trial for an mRNA-based cancer therapy.
Moderna and Merck announced on Wednesday that their experimental personalized cancer vaccine, intismeran, demonstrated positive results in a late-stage clinical trial for melanoma. The companies reported that the treatment, when combined with Merck's immunotherapy drug Keytruda (pembrolizumab), reduced the risk of cancer recurrence and slowed its spread to other organs in patients with high-risk melanoma that had been surgically removed.
The trial met its primary goal of improving recurrence-free survival and its secondary goal of preventing distant metastasis, according to reports from multiple outlets including ABC Australia, CBS News, and The Economic Times. The study enrolled 1,137 patients with stage IIB to stage IV melanoma, who were randomly assigned to receive either the combination therapy or Keytruda alone for about a year.
Professor Georgina Long, the study's principal investigator and medical director of Melanoma Institute Australia, called the results "a landmark moment for adjuvant melanoma treatment," adding that this is the first Phase 3 study to show intismeran can reduce the risk of recurrence or death in these patients. Moderna CEO Stéphane Bancel described the findings as "a pivotal moment for the field of cancer research."
The companies have not yet published the full data in a peer-reviewed journal or released specific figures on the magnitude of the improvement, as reported by NBC10 Boston and TIME. They plan to present the data at an upcoming medical meeting and share it with regulatory authorities, with Merck's R&D chief Dean Li indicating that discussions with regulators are expected to begin within the next few months.
How the Vaccine Works
Intismeran is a personalized cancer vaccine built on messenger RNA (mRNA) technology, the same platform used in Moderna's COVID-19 vaccine. The treatment works by taking a sample of the patient's tumor, identifying its unique mutational "fingerprint," and creating mRNA sequences that the immune system can use to recognize and attack cancer cells. Unlike conventional vaccines that prevent disease, this is a "therapeutic vaccine" that treats melanoma after surgery.
The manufacturing process takes about six weeks, with up to 34 mutations used to produce the bespoke vaccine, according to Jane Healy, head of oncology early development at Merck. The mRNA platform's ability to generate genetic sequences quickly is considered a significant advantage.
Keytruda, which works by revealing cancer cells that hide from the immune system, is already the standard of care for this stage of melanoma. The first approval of Keytruda for melanoma was in 2014, and the combination now offers a new treatment option for patients.
Market and Financial Impact
Investors reacted strongly to the news. Moderna's shares more than doubled in pre-market trading on Wednesday, with reports citing surges from 90% to 160%, depending on the outlet. By morning trading, shares were up 145% to $154.48, after hitting an intraday high of $163. Merck's stock rose more than 10% to $149.52.
This surge has added billions to the net worth of Moderna's founders and early investors, according to Forbes, which estimated stock gains of $1.7 billion for Robert Langer, $184 million for Noubar Afeyan, and $2.5 billion for Stéphane Bancel among others. The company's stock nonetheless remains well below its pandemic-era peak in 2021.
Even with the rally, Moderna's financial position is still recovering from the fall in demand for COVID-19 vaccines. Among the new deals, the potential revenue from intismeran is significant—Wells Fargo analysts place the therapy's annual sales potential at around $25 billion by 2035. However, questions remain about the cost and feasibility of producing patient-specific treatments at a large scale.
The experts also note that the current trial is ongoing and will need to assess overall survival rates and potential long-term side effects. The earliest regulatory approval could come in 2027, according to Bancel.
Perspectives
Professor Georgina Long, principal investigator and medical director of Melanoma Institute Australia: She stated the results are a "landmark moment" for adjuvant melanoma treatment, emphasizing it's the first Phase III study to show that the personalized cancer vaccine can reduce the risk of recurrence or death.
Stéphane Bancel, CEO of Moderna: Bancel called the findings "a pivotal moment for the field of cancer research" and said the company's goal is to turn "science fiction into a reality" with mRNA-based therapies for cancer.
Dr. Dean V. Li, President of Merck Research Laboratories: Li expressed the aim of increased cure rates for more patients, with the potential to redefine melanoma treatment.
Quotes and Analysis: Several financial analysts, including those at Barclays, noted the vaccine's sales potential, while analysts like Myles Minter of William Blair and others at JPMorgan evaluated its significance for Moderna's future profit. Practical challenges such as high costs and technical complexity were also highlighted by sources including The Chicago Tribune and The Irish Times.
How each outlet told it
ABC Australia
Framing: Headline emphasizes 'landmark' drug and prevention of recurrence, focusing on the medical breakthrough. — Optimistic and authoritative, using 'landmark' and 'breakthrough'.
Facts Included:
Merck and Moderna say experimental melanoma drug prevented recurrence in large clinical trial.
Drug called 'intismeran autogene', based on mRNA technology behind Covid-19 vaccines.
First time an mRNA treatment has shown positive results in Phase 3 trial.
When delivered with pembrolizumab, prevented recurrence and spread.
Shares in Moderna soared 128% to $US143 ($200); Merck up more than 10% to $US149.50.
Trial lasted approximately a year, involved 1,137 patients, randomized with two-thirds receiving new treatment plus pembrolizumab, rest pembrolizumab alone.
Companies will present data at upcoming conference and begin regulatory filings.
Quote from Georgina Long: 'landmark moment for adjuvant melanoma treatment'.
Long: 'Intismeran in combination with pembrolizumab has the potential to establish a new treatment paradigm.'
Treatment works by taking sample of tumor, identifying unique mutational signature, using mRNA technology.
mRNA technology uses synthetic instructions wrapped in fat bubbles to teach body to make proteins.
Technology came to fore during Covid-19 pandemic.
Melanoma one of deadliest skin cancers, more than 330,000 new cases worldwide in 2022.
Quote from CEO Stephane Bancel: 'Together with Merck, we are now studying intismeran... across multiple tumour types and stages, including melanoma, lung, bladder and kidney cancers.'
Framing: Headline emphasizes the unveiling of the vaccine and its effect on cutting spread, focusing on the medical breakthrough rather than financial or regulatory angles. — Optimistic and forward-looking, supported by quotes like 'a major success in a new field of cancer treatment' and 'auspicious start'.
Facts Included:
Moderna and Merck announced that mRNA-based cancer vaccine Intismeran reduced the risk of recurrence and spread of melanoma in a late-stage trial.
Interim results released on Wednesday met goals of reducing recurrence and preventing spread.
Detailed results not yet released, expected at an upcoming medical meeting.
Moderna President Stephen Hoge said thousands of patients could benefit by next year if approved.
National Cancer Institute: more than 1.5 million people in US living with melanoma in 2023.
Vaccine tested with immunotherapy drug Keytruda.
First positive late-stage trial result for an mRNA cancer vaccine.
Merck said companies are in talks with regulators about treatment.
Karen Knudsen, CEO of Parker Institute, said results could signal a new era for immunotherapy.
Mention of Trump administration cutting funding for mRNA research.
Framing: Headline emphasizes unveiling and cutting spread, focusing on the medical breakthrough. — Optimistic and authoritative, with quotes like 'major success' and 'new era'.
Facts Included:
Moderna and Merck announced that personalized mRNA cancer vaccine Intismeran reduced risk of recurrence and spread in late-stage trial.
Interim results released on Wednesday met both goals.
Detailed results not yet released, expected at upcoming medical meeting.
Moderna President Stephen Hoge said thousands of patients could benefit by next year if approved.
National Cancer Institute: more than 1.5 million people in US living with melanoma in 2023.
Vaccine tested with Keytruda.
Vaccine trains immune system to fight tumors by targeting mutations.
Similar approaches being tested for lung, breast, pancreatic cancers.
Previous studies suggested mRNA vaccines could help in mice and medical records.
Findings came at time when Trump administration cut funding for mRNA research.
First positive late-stage trial result for an mRNA cancer vaccine.
Merck said companies already in talks with regulators.
Framing: Headline emphasizes the stock price surge and success, linking to COVID-era reputation. — Optimistic and investment-focused, with phrases like 'landed on something' and 'right direction'.
Facts Included:
Moderna stock surged as much as 160% to $163.47 on Wednesday.
Partnership with Merck on melanoma drug trial.
CEO Stephane Bancel quote: 'These Phase 3 findings represent a pivotal moment for the field of cancer research.'
Vaccine reduces recurrence of melanoma, given alongside Keytruda.
Stock is still down roughly two-thirds from peak of $484 in August 2021.
Framing: Headline emphasizes stock doubling and 'landmark moment', mixing financial and medical significance. — Optimistic and enthusiastic, using words like 'landmark' and 'pivotal'.
Facts Included:
Moderna stock more than doubled on Wednesday morning.
Vaccine prevented melanoma from returning or spreading.
Shares surged $91.52, or 145%, to $154.48 in morning trading, intraday high of $163.
Merck shares rose $14.35, or 10.6%, to $149.52.
Study tested intismeran in combination with Keytruda.
Plan to present unpublished data to regulators at upcoming international medical meeting.
Quote from Professor Georgina Long: 'Today's results represent a landmark moment for adjuvant melanoma treatment.'
Long said first study to show treatment can reduce risk of recurrence or death.
Statistic: More than 234,680 cases of melanoma will be diagnosed in US in 2026 (Skin Cancer Foundation).
Quote from Dr. Dean Y. Li: adjuvant therapy goal is to increase possibility of cure.
Quote from Stephane Bancel: 'pivotal moment for the field of cancer research.'
Framing: Headline emphasizes stock doubling and 'landmark moment', mixing financial and medical significance. — Optimistic and enthusiastic, using words like 'landmark' and 'pivotal'.
Facts Included:
Moderna stock more than doubled on Wednesday morning.
Vaccine prevented melanoma from returning or spreading.
Shares surged $91.52, or 145%, to $154.48 in morning trading, intraday high of $163.
Merck shares rose $14.35, or 10.6%, to $149.52.
Study tested intismeran in combination with Keytruda.
Plan to present unpublished data to regulators at upcoming international medical meeting.
Quote from Professor Georgina Long: 'Today's results represent a landmark moment for adjuvant melanoma treatment.'
Long said first study to show treatment can reduce risk of recurrence or death.
Statistic: More than 234,680 cases of melanoma will be diagnosed in US in 2026 (Skin Cancer Foundation).
Quote from Dr. Dean Y. Li: adjuvant therapy goal is to increase possibility of cure.
Quote from Stephane Bancel: 'pivotal moment for the field of cancer research.'
Framing: Headline emphasizes stock doubling and 'landmark moment', mixing financial and medical significance. — Optimistic and enthusiastic, using words like 'landmark' and 'pivotal'.
Facts Included:
Moderna stock more than doubled on Wednesday morning.
Vaccine prevented melanoma from returning or spreading.
Shares surged $91.52, or 145%, to $154.48 in morning trading, intraday high of $163.
Merck shares rose $14.35, or 10.6%, to $149.52.
Study tested intismeran in combination with Keytruda.
Plan to present unpublished data to regulators at upcoming international medical meeting.
Quote from Professor Georgina Long: 'Today's results represent a landmark moment for adjuvant melanoma treatment.'
Long said first study to show treatment can reduce risk of recurrence or death.
Statistic: More than 234,680 cases of melanoma will be diagnosed in US in 2026 (Skin Cancer Foundation).
Quote from Dr. Dean Y. Li: adjuvant therapy goal is to increase possibility of cure.
Quote from Stephane Bancel: 'pivotal moment for the field of cancer research.'
Framing: Headline emphasizes the therapy averting recurrence, focusing on the clinical benefit. — Measured and analytical, using 'welcome development' and 'key questions'.
Facts Included:
Personalized vaccine developed by Moderna and Merck helped reduce recurrence of melanoma in large late-stage trial.
Trial met main goal of reducing recurrence compared to Keytruda alone, and secondary goal of slowing spread.
Moderna shares more than doubled in pre-market, Merck rose as much as 9.5%.
First positive final-stage trial for any mRNA-based cancer therapy.
Details on recurrence-free survival not released; trial ongoing to assess overall survival.
Melanoma: ~112,000 diagnosed and 8,500 deaths per year in US.
Companies will discuss filing for approval with regulators, present data at upcoming meeting.
CEO Bancel in interview said product could be approved as soon as 2027.
Bancel quote: 'It is an extraordinary milestone for mRNA science.'
Questions remain about cost and feasibility of producing bespoke treatments at scale.
Need to prove vaccine works in other tumor types.
Vaccine called intismeran autogene, developed over a decade.
Takes six weeks to make shot; analyses tumor mutations; algorithm identifies up to 34 mutations.
Jane Healy, head of oncology early development at Merck, explained process.
In trial, vaccine given with Keytruda to patients after surgery; control group had Keytruda alone.
Mid-stage trial: 49% less likely to die or have cancer return after five years.
Framing: Headline focuses on the stock surge and the trial success, emphasizing the financial impact. — Neutral and market-focused, using phrases like 'rallied', 'hope for future growth', and 'strengthen investor sentiment'.
Facts Included:
Moderna shares rallied about 159% to a high of $163.47 on Wednesday.
Stock later trading at $143.51, closed previous session at $62.96.
Interim results showed Intismeran met primary goal of reducing recurrence and secondary of preventing spread.
First successful late-stage trial of an mRNA cancer vaccine.
First study to show adding another treatment to Keytruda worked better than Keytruda alone for melanoma.
Merck shares gained 11% to $150.14.
William Blair analyst Myles Minter said results put companies in strong position for regulatory approval.
Merck R&D chief Dean Li told CNBC discussions with regulators expected within months.
Barclays analysts estimated therapy could generate $3 billion in melanoma-related sales by 2035.
JP Morgan analysts said launch as adjuvant treatment crucial to Moderna's return to profitability.
Trial enrolled 1,137 high-risk patients with stage IIB to stage IV melanoma.
Participants received up to nine doses of vaccine with Keytruda or Keytruda alone for about a year.
No new safety concerns emerged.
In January, mid-stage study showed combination reduced risk of recurrence or death by 49%.
CEO Stephane Bancel said pricing not decided.
Treatment does not use patient's own cells, allowing scale-up and cost reduction.
1.5 million people in US living with melanoma in 2023.
Framing: Headline focuses on the founder's billionaire status, framing the news as a wealth story. — Informative and wealth-focused, with a celebratory tone for the founder.
Facts Included:
Moderna co-founder Robert Langer is a billionaire once again as shares doubled.
Langer's equity rose to about $1.7 billion from $730 million on Tuesday.
His stake was estimated at $343 million when shares hit low of $29.81 on Jan. 2.
Co-founder Noubar Afeyan's net worth jumped $184 million to $2.1 billion.
CEO Stephane Bancel's fortune swelled $2.5 billion to $4.8 billion.
Founding investor Timothy Springer's net worth increased by $948 million to $2.2 billion.
Moderna shares rocketed by 156% to around $161 as of Wednesday morning.
Vaccine is mRNA-based shot combined with Keytruda, marked first successful final-stage study for mRNA cancer therapy.
Drug helped cut recurrence of severe skin cancer and extended time before melanoma returned.
Reference to further reading: Forbes article on shares skyrocketing 90%.
Framing: Headline emphasizes that hype is ahead of the math, focusing on financial reality versus market enthusiasm. — Critical and skeptical, with phrases like 'sobering math', 'cold realities', and 'overshooting reality'.
Facts Included:
Moderna's stock surged 177% in a single session, largest one-day surge for an S&P 500 company in over two decades.
Moderna's market value rose to near $60 billion from $25 billion pre-announcement.
Trio (Moderna, Merck, BioNTech) added $80 billion in market cap.
Vaccine personalized, analyzes up to 34 mutations, but typically only 2-3 generate meaningful immune response.
Analyst Daina Graybosch models low-single-digit billions in annual sales by 2032, bull case $10 billion.
Melanoma is unusually well-suited due to abundance of mutations and sensitivity to immunotherapy.
Kidney cancer has fewer mutations, bladder cancer has suppressive environment, pancreatic cancer resistant.
Production is bespoke, costing ballpark $300,000 based on comparable therapies.
Potential pricing issues in Europe and US due to Trump policies tying prices.
Gross margins initially 50-80% vs conventional drugs 90%+.
RBC analyst Luca Issi says market pricing in possibility of next Keytruda/Opdivo, but could be narrower.
Bigger promise is prevention in high-risk people, but far off.
Framing: Headline emphasizes promise and stock skyrocketing, focusing on investor reaction and potential. — Optimistic and enthusiastic, with words like 'big moment', 'pivotal', 'promise'.
Facts Included:
Moderna and Merck jointly announced positive results from late-stage trial.
mRNA-based shot combined with Keytruda hit goals in third phase trial involving 1,100 patients.
Moderna CEO Stephane Bancel quote: 'It's a big moment for medicine, a big moment for patients.'
Moderna stock closed at $62.51 Tuesday, surpassed $144 early Wednesday.
Merck stock initially jumped 8%.
Clinical trial focused on melanoma.
Bancel described findings as 'pivotal moment'.
Quote from Bancel: 'For many years, the idea of creating an mRNA treatment... was aspirational.'
Professor Georgina Long quote: 'first Phase 3 study that showed intismeran... can help reduce recurrence or death.'
Long: 'Intismeran in combination with pembrolizumab has the potential to establish a new treatment paradigm.'
Dr. Dean Y. Li quote about adjuvant therapy and potential to redefine stage 4 melanoma treatment.
INTerpath program consists of nine total Phase 2 and Phase 3 trials across multiple tumor types including melanoma, NSCLC, bladder, renal cell.
Framing: Headline emphasizes the boost to both companies and the milestone, focusing on the positive trial outcome. — Measured and factual, with phrases like 'important milestone' and 'welcome respite'.
Facts Included:
Shares in Moderna and Merck soared after trial results.
Trial met main goal of reducing melanoma recurrence compared to Keytruda alone.
Also met secondary goal of slowing spread.
First positive final-stage trial for any mRNA-based cancer therapy.
For Merck, facing patent loss for Keytruda, offers new market.
Moderna shares more than doubled in pre-market, Merck rose almost 9%.
Details on recurrence-free survival not released, trial ongoing for overall survival.
Melanoma statistics: ~112,000 diagnosed and 8,500 deaths per year in US (American Cancer Society).
Companies will discuss filing for approval, present data at upcoming medical meeting.
CEO Bancel said product could be approved as soon as 2027.
Vaccine called intismeran autogene, developed over a decade.
Takes about six weeks to make shot; analyzes tumor mutations.
Algorithm identifies up to 34 mutations.
Jane Healy, head of oncology early development at Merck, explained process.
In trial, vaccine given with Keytruda to patients after surgery; control group had Keytruda alone.
Mid-stage trial results: 49% less likely to die or have cancer return after five years.
Framing: Headline emphasizes 'promise' and the companies, focusing on the potential. — Cautious and measured, using 'signs of preventing' and 'appeared to extend'.
Facts Included:
Moderna and Merck said experimental mRNA vaccine showed signs of preventing cancer recurrence or spread in high-risk melanoma patients.
Companies have not published results in peer-reviewed journal, nor released new data.
Data to be presented at upcoming medical meeting and shared with regulators.
Vaccine called Intismeran, produced by Merck and Moderna, used with Keytruda.
Interim results extended time before cancer returned.
First-ever breakthrough of its kind.
Study to examine overall survival rates.
Quote from Stephane Bancel: 'These Phase 3 findings represent a pivotal moment for the field of cancer research.'
Moderna shares soared as much as 106% in pre-market trading; Merck up 7%.
Framing: Headline emphasizes 'promise' and the companies, focusing on the potential. — Cautious and measured, using 'signs of preventing' and 'appeared to extend'.
Facts Included:
Moderna and Merck said experimental mRNA vaccine showed signs of preventing cancer recurrence or spread in high-risk melanoma patients.
Companies have not published results in peer-reviewed journal, nor released new data.
Data to be presented at upcoming medical meeting and shared with regulators.
Vaccine called Intismeran, produced by Merck and Moderna, used with Keytruda.
Interim results extended time before cancer returned.
First-ever breakthrough of its kind.
Study to examine overall survival rates.
Quote from Stephane Bancel: 'These Phase 3 findings represent a pivotal moment for the field of cancer research.'
Moderna shares soared as much as 106% in pre-market trading; Merck up 7%.
Framing: Headline emphasizes the trial success and the companies, focusing on the positive result. — Neutral and factual, with a focus on business impact.
Facts Included:
Moderna's mRNA vaccine combined with Keytruda succeeded in late-stage trial for skin cancer.
Shares of vaccine maker up 60% in premarket trading.
Interim results found treatment met primary target of reducing recurrence and secondary goal of keeping cancers from spreading.
Moderna diversifying beyond Covid-19 vaccine; recently added FDA-approved flu vaccine, developing shots for norovirus and Lyme.
Barclays analysts expect therapy could generate about $3 billion for treating melanoma by 2035.
Shares trading at $103.60, Merck climbed 7.5% premarket.
Treatment combines Keytruda with made-to-order mRNA vaccine based on analysis of mutations in patient's tumors.
Trial enrolled 1,137 high-risk patients with stage IIB-IV melanoma.
Volunteers randomized to receive up to nine doses of Keytruda plus vaccine or Keytruda alone for about a year.
No new safety signals emerged.
In January, mid-stage trial showed reduced risk of recurrence or death by 49% after five years.
Companies will present results at upcoming medical meeting and share with regulators.
Melanoma is deadliest form of skin cancer; 1.5 million in US living with melanoma in 2023.
Framing: Headline focuses on 'Promising Results' and the partnership, emphasizing hope and potential. — Optimistic and educational, with phrases like 'significant benefit' and 'transformational'.
Facts Included:
Intismeran, jointly developed by Moderna and Merck, with Keytruda improved recurrence-free survival and reduced spread compared to Keytruda alone.
Study included 1,137 people with stage 2 to 4 melanoma after surgery.
Intismeran is a therapeutic vaccine that studies patient's cancer mutations, makes mRNA sequences to teach immune system.
mRNA platform can generate sequences in weeks, essential for scaling.
Keytruda works by unveiling cancer cells.
Earlier study at ASCO showed combination lowered risk of recurring melanoma by 49% and distant spread or death by 59%.
Moderna stock dropped after pandemic highs; in 2025 Bancel laid off 10% workforce (500-800 employees).
FDA approved first mRNA flu shot in August, after initially refusing to review.
Bancel says exploring intismeran alone, and in earlier stage cancers.
Bancel explains combining with Keytruda was for ethical reasons.
Studying intismeran in stage 1 and 3 lung cancer, and in kidney, pancreas, bladder (nine ongoing studies).
Framing: Headline emphasizes the 'landmark moment' and the trial's success, focusing on medical significance. — Optimistic and celebratory, using 'landmark' and 'pivotal'.
Facts Included:
Cancer vaccine developed by Merck and Moderna showed positive and promising late-stage results.
Trial included more than 1,137 patients with high-risk or advanced melanoma surgically removed.
Met primary goals of recurrence-free survival and distant metastasis-free survival.
Quote from Professor Georgina Long: 'Today's results represent a landmark moment for adjuvant melanoma treatment.'
Long: first Phase 3 study to show intismeran with pembrolizumab can reduce risk of recurrence or death.
mRNA vaccine will continue under Phase 3 study.
Plan to present data at upcoming international medical meeting and to regulatory authorities.
Melanoma causes largest share of skin cancer-related deaths despite being about 1% of cases.
Quote from Stephane Bancel: 'These Phase 3 findings represent a pivotal moment for the field of cancer research.'
Note: Additional photo caption about President Trump on helipad (unrelated).
Framing: Headline emphasizes the stock surge and 'claimed' breakthrough, introducing a skeptical note. — Mixed - cautiously optimistic with a critical edge, using 'claimed' and mentioning political funding issues.
Facts Included:
Moderna stock more than doubled on Wednesday after reporting successful results from mRNA melanoma cancer vaccine.
mRNA shot in combination with Keytruda met critical benchmarks in global late-stage trial of more than 1,100 patients.
Merck stock climbed more than 10%.
CEO Stephane Bancel wrote in blog post: 'extraordinary milestone for Moderna, for mRNA science, and most importantly, for patients with cancer.'
Bancel: 'For many years, the idea that we could take the unique genetic fingerprint of a patient's tumor and use mRNA to create a medicine designed specifically for that individual patient's cancer sounded like science fiction.'
Cancer vaccines using mRNA train immune system to identify and destroy tumor cells, uniquely created for each patient.
Initial data suggests vaccine and Keytruda could serve as new treatment option for melanoma.
Melanoma makes up only about 1% of skin cancers but causes majority of skin cancer deaths.
Moderna was one of the pharmaceutical giants that rushed to create mRNA vaccine during COVID-19 pandemic, but financial prospects fell.
Stock still trading at less than a third of 2021 peak.
New development comes as Trump administration revoked research funding for mRNA vaccines for upper respiratory infections and downplayed their importance.
Bancel argued investment in mRNA technology for cancer will revolutionize cancer medicine.
Framing: Headline emphasizes the 'claim' and encouraging results, with a cautious tone. — Neutral and cautious, using 'claim' and 'encouraging results'.
Facts Included:
Merck and Moderna announced encouraging results from trial of experimental vaccine against melanoma.
Vaccine called intismeran autogene showed 'statistically significant and clinically meaningful improvements' with Keytruda.
Therapeutic vaccines treat rather than prevent disease.
Shares in Moderna soared in early New York trading, up more than 90% to around $120.
Merck stock up 10%.
First positive Phase 3 readout for an individualised neoantigen therapy and mRNA-based cancer therapy.
mRNA technology proved highly effective against Covid-19.
Each row is one claim, attributed to the outlet whose wording states it most clearly. Confidence rates how directly the source text states the claim — explicit and unhedged rates high; hedged, pieced-together, or internally inconsistent statements rate lower. It does not measure whether the claim is true. Status counts the distinct outlets we found asserting it — so a single-source claim can still show high confidence, and a multi-source claim can show medium. Every one of those outlets is named beside the status, so you can check the count against the list. For claims extracted before we began storing that list, the row says so: it names the outlet the claim is quoted from and states that we have not recorded which outlets backed it. Outlets wrote at different times, so a figure that evolves — a casualty count, for example — can legitimately differ between rows; check the "as of" time next to each claim's source.
Claim
Confidence
Status
ClaimModerna and Merck announced positive results from a late-stage trial of the melanoma vaccine intismeran (autogene), used in combination with Keytruda.
ClaimThe trial met its primary goal of reducing melanoma recurrence and its secondary goal of preventing the cancer from spreading to other parts of the body.
ClaimParticipants were randomly assigned to receive up to nine doses of the personalised vaccine alongside Keytruda, or Keytruda alone, for about one year.
ClaimThe trial is the first Phase 3 study to show that adding intismeran to Keytruda works better than Keytruda alone in patients with surgically removed melanoma.
ClaimBancel said the treatment does not use a patient's own cells, which could allow the manufacturing process to be scaled up and costs to be reduced.
ClaimIntismeran is an autogene therapy that studies a patient's cancer mutations, makes mRNA sequences of those mutations, and gives them back to the patient.
ClaimDr. Dean Y. Li, president of Merck Research Laboratories, said the goal of adjuvant therapy is to increase the possibility of cure for more patients.
ClaimAn algorithm identifies which mutations are most likely to provoke an immune response, and up to 34 of them are used to produce the personalized vaccine, said Jane Healy, head of oncology early development at Merck.
ClaimModerna has been diversifying its portfolio beyond its COVID-19 vaccine, recently adding an FDA-approved flu vaccine and developing shots for norovirus and Lyme disease.
ClaimThe INTerpath program consists of nine total Phase 2 and Phase 3 clinical trials across multiple tumor types, including melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma.
ClaimBancel wrote in a blog post that the trial results mark 'an extraordinary milestone for Moderna, for mRNA science, and most importantly, for patients with cancer.'
ClaimIn the trial, the mRNA vaccine was given in combination with Keytruda to patients after their tumors were surgically removed; a control group received Keytruda alone.
ClaimThe companies said earlier this year that skin cancer patients in a mid-stage trial who got the mRNA shot with Keytruda were 49% less likely to die or have their cancer return after five years than those who received Keytruda alone.
15 outlets · 17 articles consulted: ABC Australia, africa.businessinsider.com, CBS News, Chicago Tribune, The Economic Times, Forbes, International Business Times, The Irish Times, NBC10 Boston, NBC 5 Chicago, News24, TIME, UPI News, Washington Examiner, South China Morning Post72 claims extractedVersion 3Written 2026-08-19